“LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING”. Mediterranean Journal of Hematology and Infectious Diseases, vol. 13, no. 1, Oct. 2021, p. e2021065, https://doi.org/10.4084/MJHID.2021.065.